SpaceX deal for xAI puts Elon Musk to test
Digest more
Veradermics is set to raise $200 million in an IPO to fund its novel extended-release oral minoxidil for pattern hair loss. Learn more about MANE stock here.
Aktis Oncology exceeded its own expectations for its IPO in a good omen for those hoping for a more inviting public market this year. The company, which has accrued an impressive list of Big Pharma backers in its previous funding rounds, estimated earlier ...
The public trading debut of medical supply giant Medline will go down as the biggest global IPO of 2025. That’s impressive in and of itself, but it’s even more impressive given that the company is not even a bit player in the artificial intelligence space.
SoftBank-backed Lenskart had a muted debut on the exchanges as its shares traded down 11% at the open. The issue was subscribed to over 28 times, with strong participation from institutional investors and high-net-worth individuals. The IPO created buzz on ...
KOID ETF offers diversified humanoid robotics exposure as China’s 2026 IPO wave reshapes holdings—capture growth across hardware, chips, sensors and metals. See more.
New research from University of Notre Dame accountancy professor Brad Badertscher examines the prevalence, determinants and consequences of cheap stock, finding the average firm’s IPO price is more than five times the exercise price (price per share when stock options are exercised) of options issued in the fiscal year before the IPO.
Coatue Management's founder and portfolio manager said the market today bears little resemblance to the vibrant IPO pipeline of prior decades. "Twenty or 30 years ago, there were so many more IPOs than today. There's very few IPOs ... there's almost none ...
Why the IPO market took off in 2025. In this podcast, Motley Fool analysts Emily Flippen and Sanmeet Deo and contirubtor Jason Hall break down why the IPO market took off in 2025, which new listings may look like future Rule Breakers, and what investors ...
The Mills family cashed out a majority stake in the family’s medical supplies firm to private equity in 2021. But the coming $50 billion IPO shows that even what they continue to hold is worth a fortune. Medical-supplies giant Medline’s IPO is set to ...